智通财经APP获悉，基石药业-B(02616)涨近7%，截至发稿，涨6.81%，报5.49港元，成交额3518.91万港元。
消息面上，基石药业核心资产CS2009（PD-1/VEGF/CTLA-4三特异性抗体）的最新临床数据将于2026年10月举行的欧洲肿瘤内科学会（ESMO）年会上以两项快速口头报告形式披露。此外，公司首席执行官、研发总裁及执行董事杨建新于9月17日至22日以个人资金在公开市场上合共购买49.6万股公司股份，总代价逾270万港元。
据悉，自2022年8月担任首席执行官以来，杨建新博士已于公开市场累计购买超1421万股公司股份。此次股份购买充分彰显杨博士对公司的长期承诺以及对公司未来业务前景的坚定信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.